

Introducing Acutis PGx Pharmacogenomics Testing

Ineffective medications and adverse drug events are drug therapy problems prescribers face when treating patients PGx testing is one solution prescribers can use to prevent or resolve ineffective medications and adverse drug events.

Acutis PGx test includes:  + 

...And Covers Pain and Psychiatry Areas

■ Pain

- NSAIDs
- Opioids
- Opioid Dependencies
- Muscle Relaxants

■ Psychiatry

- Anticonvulsants
- Antidepressants
- Antipsychotics
- Tricyclic Antidepressants

The Acutis Difference: Quality



Acutis is a **CLIA and CAP accredited laboratory** committed to providing innovative diagnostic testing and clinical decision support tools to aid physicians in improving their patients' medication therapy management outcomes.



Acutis' PGx test is a **NYSDOH approved laboratory developed test**. This means our test has met the most rigorous validation process.

Transparency

Pharmacists and clinical scientists regularly research literature and update our test to ensure it includes **the most up-to-date drug-gene pairs with the Highest Levels of Clinical Utility**.

Our Acutis Pharmacogenomics Report

Results Summary

Current Patient Medications

Codeine - X

Codeine;
Fioricet® with Codeine

Condition Risk Factors

Antipsychotic-Induced Tardive Dyskinesia - !

Potentially Impacted Medications

Category	Drug Class	Standard Precautions	Use with Caution	Consider Alternatives
Anesthesia	Inhaled Anesthetics	✓		X

Anticancer Agents

Antihistamines

Test Details

Gene	Results	Phenotype	Alleles Tested
ABCB1	1236T>C T/C 2677G>A G/G	Heterozygous - Variant Allele Present Variant Allele Not Present	3435C>T, 1236T>C, 2677G>A, 2677G>T

Dosing Guidance

Amitriptyline - X

Elavil®

Abnormal Amitriptyline Exposure (CYP2D6: Intermediate or Normal or Ultra-rapid Metabolizer; CYP2C19: Normal Metabolizer) | Evidence Strength: STRONG | Primary Source: CPIC

Based on the genotype result, this patient MAY be a CYP2D6 intermediate or ultra-rapid metabolizer, although the result is not definitive. The patient's phenotype is abnormal exposure to amitriptyline and its metabolites.

Psychiatric Conditions: Consider dose adjustments. Neuropathic Pain: Consider therapeutic drug monitoring to guide dose. patient's clinical response to treatment.

Easy to read test report that includes:

Translated into actions to save you time

Acutis' easy to navigate test report helps prescribers

- Select medications most efficacious for the patient
- Select the medications least likely to cause the patient a gene-drug related adverse drug reaction
- Lower the risk of phenoconversion
- Adjust patients' medication dosages
- Decrease trial and error prescribing

We offer unparalleled customer support, including a PharmD available to assist prescribers with test results.

Contact us today to get started with Acutis PGx
844-522-8847

service@acutis.com
acutis.com

68 Culver400 Karin Lane, Hicksville, NY 11801
Fax 631-532-1680